{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T04:24:17Z","timestamp":1747887857217,"version":"3.41.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"DOI":"10.1038\/s41398-025-03272-z","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T17:42:28Z","timestamp":1747849348000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Psychiatric and cognitive function in patients with serotonin producing neuroendocrine tumors"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0435-8566","authenticated-orcid":false,"given":"Maryse J.","family":"Luijendijk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margot E. T.","family":"Tesselaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5757-9779","authenticated-orcid":false,"given":"Huub H.","family":"van Rossum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9142-6263","authenticated-orcid":false,"given":"Martijn","family":"van Faassen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catharina M.","family":"Korse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wieke H. M.","family":"Verbeek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jocelyn R.","family":"Spruit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pernilla C.","family":"Scheelings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva H.","family":"Hooghiemstra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ido P.","family":"Kema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6072-0358","authenticated-orcid":false,"given":"Henricus G.","family":"Ruh\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanne B.","family":"Schagen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4099-2385","authenticated-orcid":false,"given":"Froukje E.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"key":"3272_CR1","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1007\/s00520-020-05860-9","volume":"29","author":"SJ Mayo","year":"2021","unstructured":"Mayo SJ, Lustberg M, Haryana MD, Nakamura ZM, Allen DH, Von Ah D, et al. Cancer-related cognitive impairment in patients with non-central nervous system malignancies: an overview for oncology providers from the MASCC Neurological Complications Study Group. Support Care Cancer. 2021;29:2821\u201340.","journal-title":"Support Care Cancer"},{"key":"3272_CR2","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3109\/09540261.2013.864260","volume":"26","author":"MC Janelsins","year":"2014","unstructured":"Janelsins MC, Kesler SR, Ahles TA, Morrow GR. Prevalence, mechanisms, and management of cancer-related cognitive impairment. Int Rev Psychiatry. 2014;26:102\u201313.","journal-title":"Int Rev Psychiatry"},{"key":"3272_CR3","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1200\/JCO.2014.56.0086","volume":"32","author":"A Mehnert","year":"2014","unstructured":"Mehnert A, Brahler E, Faller H, Harter M, Keller M, Schulz H, et al. Four-week prevalence of mental disorders in patients with cancer across major tumor entities. J Clin Oncol. 2014;32:3540\u20136.","journal-title":"J Clin Oncol"},{"key":"3272_CR4","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/S1470-2045(11)70002-X","volume":"12","author":"AJ Mitchell","year":"2011","unstructured":"Mitchell AJ, Chan M, Bhatti H, Halton M, Grassi L, Johansen C, et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol. 2011;12:160\u201374.","journal-title":"Lancet Oncol"},{"key":"3272_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101328","volume":"16","author":"D Riedl","year":"2022","unstructured":"Riedl D, Sch\u00fc\u00dfler G. Factors associated with and risk factors for depression in cancer patients - A systematic literature review. Transl Oncol. 2022;16:101328.","journal-title":"Transl Oncol"},{"key":"3272_CR6","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1177\/0004867419888576","volume":"54","author":"JD Rosenblat","year":"2020","unstructured":"Rosenblat JD, Kurdyak P, Cosci F, Berk M, Maes M, Brunoni AR, et al. Depression in the medically ill. Aust N Z J Psychiatry. 2020;54:346\u201366.","journal-title":"Aust N Z J Psychiatry"},{"key":"3272_CR7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S1470-2045(07)70410-2","volume":"9","author":"IM Modlin","year":"2008","unstructured":"Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9:61\u201372.","journal-title":"Lancet Oncol"},{"key":"3272_CR8","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13146","volume":"34","author":"S Grozinsky-Glasberg","year":"2022","unstructured":"Grozinsky-Glasberg S, Davar J, Hofland J, Dobson R, Prasad V, Pascher A, et al. European Neuroendocrine Tumor Society (ENETS) 2022 guidance paper for carcinoid syndrome and carcinoid heart disease. J Neuroendocrinol. 2022;34:e13146.","journal-title":"J Neuroendocrinol"},{"key":"3272_CR9","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1470-2045(17)30110-9","volume":"18","author":"DM Halperin","year":"2017","unstructured":"Halperin DM, Shen C, Dasari A, Xu Y, Chu Y, Zhou S, et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol. 2017;18:525\u201334.","journal-title":"Lancet Oncol"},{"key":"3272_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.comppsych.2021.152244","volume":"109","author":"A La Salvia","year":"2021","unstructured":"La Salvia A, Portigliatti Pomeri A, Persano I, Trevisi E, Parlagreco E, Colombi N, et al. Serotoninergic brain dysfunction in neuroendocrine tumor patients: a scoping review. Compr Psychiatry. 2021;109:152244.","journal-title":"Compr Psychiatry"},{"key":"3272_CR11","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1007\/s00268-010-0404-9","volume":"34","author":"AJ Chambers","year":"2010","unstructured":"Chambers AJ, Longman RS, Pasieka JL, Dixon E, Rorstad O, Rach-Longman K, et al. Impairment of cognitive function reported by patients suffering from carcinoid syndrome. World J Surg. 2010;34:1356\u201360.","journal-title":"World J Surg"},{"key":"3272_CR12","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/SLA.0b013e318288ff6d","volume":"259","author":"JL Pasieka","year":"2014","unstructured":"Pasieka JL, Longman RS, Chambers AJ, Rorstad O, Rach-Longman K, Dixon E. Cognitive impairment associated with carcinoid syndrome. Ann Surg. 2014;259:355\u20139.","journal-title":"Ann Surg"},{"key":"3272_CR13","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1007\/s00213-003-1455-5","volume":"168","author":"S Russo","year":"2003","unstructured":"Russo S, Nielen MM, Boon JC, Kema IP, Willemse PH, de Vries EG, et al. Neuropsychological investigation into the carcinoid syndrome. Psychopharmacology. 2003;168:324\u20138.","journal-title":"Psychopharmacology"},{"key":"3272_CR14","first-page":"1","volume":"3","author":"JR Adams","year":"2019","unstructured":"Adams JR, Ray D, Willmon R, Pulgar S, Dasari A. Living with neuroendocrine tumors: assessment of quality of life through a mobile application. JCO Clin Cancer Inf. 2019;3:1\u201310.","journal-title":"JCO Clin Cancer Inf"},{"key":"3272_CR15","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1007\/s00520-018-4166-5","volume":"26","author":"VL Beesley","year":"2018","unstructured":"Beesley VL, Burge M, Dumbrava M, Callum J, Neale RE, Wyld DK. Perceptions of care and patient-reported outcomes in people living with neuroendocrine tumours. Support Care Cancer. 2018;26:3153\u201361.","journal-title":"Support Care Cancer"},{"key":"3272_CR16","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/cncr.29099","volume":"121","author":"J Hallet","year":"2015","unstructured":"Hallet J, Law CH, Cukier M, Saskin R, Liu N, Singh S. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015;121:589\u201397.","journal-title":"Cancer"},{"key":"3272_CR17","first-page":"422","volume":"66","author":"S Russo","year":"2004","unstructured":"Russo S, Boon JC, Kema IP, Willemse PH, den Boer JA, Korf J, et al. Patients with carcinoid syndrome exhibit symptoms of aggressive impulse dysregulation. Psychosom Med. 2004;66:422\u20135.","journal-title":"Psychosom Med"},{"key":"3272_CR18","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.ejphar.2014.10.031","volume":"753","author":"B Olivier","year":"2015","unstructured":"Olivier B. Serotonin: a never-ending story. Eur J Pharmacol. 2015;753:2\u201318.","journal-title":"Eur J Pharmacol"},{"key":"3272_CR19","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/sj.mp.4001949","volume":"12","author":"HG Ruhe","year":"2007","unstructured":"Ruhe HG, Mason NS, Schene AH. Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol Psychiatry. 2007;12:331\u201359.","journal-title":"Mol Psychiatry"},{"key":"3272_CR20","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/0098-2997(83)90005-5","volume":"6","author":"DA Bender","year":"1983","unstructured":"Bender DA. Biochemistry of tryptophan in health and disease. Mol Asp Med. 1983;6:101\u201397.","journal-title":"Mol Asp Med"},{"key":"3272_CR21","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1097\/01.PSY.0000078188.74020.CC","volume":"65","author":"S Russo","year":"2003","unstructured":"Russo S, Kema IP, Fokkema MR, Boon JC, Willemse PH, de Vries EG, et al. Tryptophan as a link between psychopathology and somatic states. Psychosom Med. 2003;65:665\u201371.","journal-title":"Psychosom Med"},{"key":"3272_CR22","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.neubiorev.2009.03.006","volume":"33","author":"D Mendelsohn","year":"2009","unstructured":"Mendelsohn D, Riedel WJ, Sambeth A. Effects of acute tryptophan depletion on memory, attention and executive functions: a systematic review. Neurosci Biobehav Rev. 2009;33:926\u201352.","journal-title":"Neurosci Biobehav Rev"},{"key":"3272_CR23","doi-asserted-by":"publisher","first-page":"e241","DOI":"10.1515\/cclm-2019-1111","volume":"58","author":"HH van Rossum","year":"2020","unstructured":"van Rossum HH, Spruit J, Korse CM, de Vries FE, Tesselaar MET. Antidepressant use limits serotonin as a marker for neuroendocrine tumor disease activity by lowering of circulating serotonin concentrations. Clin Chem Lab Med. 2020;58:e241\u20133.","journal-title":"Clin Chem Lab Med"},{"key":"3272_CR24","volume-title":"15-woordentest Provisional manual","author":"W Van den Burg","year":"1986","unstructured":"Van den Burg W, Saan RJ, Deelman BG. 15-woordentest Provisional manual. Groningen: Academisch Ziekenhuis Groningen, Afdeling Neuropsychologie; 1986."},{"key":"3272_CR25","unstructured":"Van Balen HGG, Zwaaftink AJMG The Rivermead behavioural memory test Handleiding Nederlandstalige bewerking. Thames Valley Test Company; 1987."},{"key":"3272_CR26","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2466\/pms.1958.8.3.271","volume":"8","author":"RM Reitan","year":"1958","unstructured":"Reitan RM. Validity of the trail making test as an indicator of organic brain damage. Percept Mot Skills. 1958;8:271\u20136.","journal-title":"Percept Mot Skills"},{"key":"3272_CR27","volume-title":"De Stroop kleur-woord test Handleiding, tweede gewijzigde druk The Stroop color-word test Manual","author":"JG Hammes","year":"1978","unstructured":"Hammes JG. De Stroop kleur-woord test Handleiding, tweede gewijzigde druk The Stroop color-word test Manual. Lisse: Swets & Zeitlinger; 1978."},{"key":"3272_CR28","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/BF03078128","volume":"39","author":"B Schmand","year":"2008","unstructured":"Schmand B, Groenink SC, van den Dungen M. Letter fluency: psychometric properties and Dutch normative data. Tijdschr Gerontol Geriatr. 2008;39:64\u201376.","journal-title":"Tijdschr Gerontol Geriatr"},{"key":"3272_CR29","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1017\/S1355617706060115","volume":"12","author":"W Van der Elst","year":"2006","unstructured":"Van der Elst W, Van Boxtel MP, Van Breukelen GJ, Jolles J. Normative data for the animal, Profession and Letter M naming verbal fluency tests for Dutch speaking participants and the effects of age, education, and sex. J Int Neuropsychol Soc. 2006;12:80\u201389.","journal-title":"J Int Neuropsychol Soc"},{"key":"3272_CR30","unstructured":"Kaplan E, Goodglass H, Weintraub S Boston naming test. (2nd ed.). Philadelphia, PA: Lea & Febiger; 2001."},{"key":"3272_CR31","volume-title":"Dutch adult reading test","author":"B Schmand","year":"1992","unstructured":"Schmand B, Lindeboom J, van Harskamp F. Dutch adult reading test. Lisse: Swets & Zeitlinger; 1992."},{"key":"3272_CR32","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. \u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189\u201398.","journal-title":"J Psychiatr Res"},{"key":"3272_CR33","volume-title":"Structured clinical interview for DSM-5 disorders, clinician version (SCID-5-CV)","author":"MB First","year":"2016","unstructured":"First MB, Williams JBW, Karg RS, Spitzer RL. Structured clinical interview for DSM-5 disorders, clinician version (SCID-5-CV). Arlington, VA: American Psychiatric Association; 2016."},{"key":"3272_CR34","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1111\/pcn.12931","volume":"73","author":"FL Os\u00f3rio","year":"2019","unstructured":"Os\u00f3rio FL, Loureiro SR, Hallak JEC, Machado-de-Sousa JP, Ushirohira JM, Baes CVW, et al. Clinical validity and intrarater and test-retest reliability of the structured clinical interview for DSM-5 - clinician version (SCID-5-CV). Psychiatry Clin Neurosci. 2019;73:754\u201360.","journal-title":"Psychiatry Clin Neurosci"},{"key":"3272_CR35","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1037\/0022-006X.56.6.893","volume":"56","author":"AT Beck","year":"1988","unstructured":"Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consulting Clin Psychol. 1988;56:893\u20137.","journal-title":"J Consulting Clin Psychol"},{"key":"3272_CR36","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1017\/S0033291700035558","volume":"26","author":"AJ Rush","year":"1996","unstructured":"Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH. The inventory of depressive symptomatology (IDS): psychometric properties. Psychological Med. 1996;26:477\u201386.","journal-title":"Psychological Med"},{"key":"3272_CR37","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365\u201376.","journal-title":"J Natl Cancer Inst"},{"key":"3272_CR38","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/bjc.2012.560","volume":"108","author":"G Yadegarfar","year":"2013","unstructured":"Yadegarfar G, Friend L, Jones L, Plum LM, Ardill J, Taal B, et al. Validation of the EORTC QLQ-GINET21 questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumours. Br J Cancer. 2013;108:301\u201310.","journal-title":"Br J Cancer"},{"key":"3272_CR39","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.psychres.2007.03.002","volume":"159","author":"KJ Craig","year":"2008","unstructured":"Craig KJ, Hietanen H, Markova IS, Berrios GE. The irritability questionnaire: a new scale for the measurement of irritability. Psychiatry Res. 2008;159:367\u201375.","journal-title":"Psychiatry Res"},{"key":"3272_CR40","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/jclp.22253","volume":"72","author":"M Lievaart","year":"2016","unstructured":"Lievaart M, Franken IH, Hovens JE. Anger assessment in clinical and nonclinical populations: further validation of the state-trait anger expression inventory-2. J Clin Psychol. 2016;72:263\u201378.","journal-title":"J Clin Psychol"},{"key":"3272_CR41","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.cca.2017.04.001","volume":"469","author":"CM Korse","year":"2017","unstructured":"Korse CM, Buning-Kager J, Linders TC, Heijboer AC, van den Broek D, Tesselaar MET, et al. A serum and platelet-rich plasma serotonin assay using liquid chromatography tandem mass spectrometry for monitoring of neuroendocrine tumor patients. Clin Chim Acta. 2017;469:130\u20135.","journal-title":"Clin Chim Acta"},{"key":"3272_CR42","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1373\/clinchem.2019.305359","volume":"65","author":"M van Faassen","year":"2019","unstructured":"van Faassen M, Bouma G, de Hosson LD, Peters MAM, Kats-Ugurlu G, de Vries EGE, et al. Quantitative profiling of platelet-rich plasma indole markers by direct-matrix derivatization combined with LC-MS\/MS in patients with neuroendocrine tumors. Clin Chem. 2019;65:1388\u201396.","journal-title":"Clin Chem"},{"key":"3272_CR43","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.3389\/fpsyg.2016.01601","volume":"7","author":"NR de Vent","year":"2016","unstructured":"de Vent NR, Agelink van Rentergem JA, Schmand BA, Murre JM, Huizenga HM. Advanced Neuropsychological Diagnostics Infrastructure (ANDI): a normative database created from control datasets. Front Psychol. 2016;7:1601.","journal-title":"Front Psychol"},{"key":"3272_CR44","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1080\/13803395.2015.1132299","volume":"38","author":"HM Huizenga","year":"2016","unstructured":"Huizenga HM, Agelink van Rentergem JA, Grasman RP, Muslimovic D, Schmand B. Normative comparisons for large neuropsychological test batteries: user-friendly and sensitive solutions to minimize familywise false positives. J Clin Exp Neuropsychol. 2016;38:611\u201329.","journal-title":"J Clin Exp Neuropsychol"},{"key":"3272_CR45","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1016\/j.neuropsychologia.2007.03.011","volume":"45","author":"HM Huizenga","year":"2007","unstructured":"Huizenga HM, Smeding H, Grasman RP, Schmand B. Multivariate normative comparisons. Neuropsychologia. 2007;45:2534\u201342.","journal-title":"Neuropsychologia"},{"key":"3272_CR46","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.jad.2009.12.020","volume":"125","author":"KJ Wardenaar","year":"2010","unstructured":"Wardenaar KJ, van Veen T, Giltay EJ, den Hollander-Gijsman M, Penninx BW, Zitman FG. The structure and dimensionality of the Inventory of Depressive Symptomatology Self Report (IDS-SR) in patients with depressive disorders and healthy controls. J Affect Disord. 2010;125:146\u201354.","journal-title":"J Affect Disord"},{"key":"3272_CR47","doi-asserted-by":"publisher","first-page":"e0187009","DOI":"10.1371\/journal.pone.0187009","volume":"12","author":"R Arjadi","year":"2017","unstructured":"Arjadi R, Nauta MH, Utoyo DB, Bockting CLH. The Inventory of Depressive Symptomatology Self Report (IDS-SR): psychometric properties of the Indonesian version. PLoS One. 2017;12:e0187009.","journal-title":"PLoS One"},{"key":"3272_CR48","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1037\/1040-3590.5.4.408","volume":"4","author":"PL Hewitt","year":"1993","unstructured":"Hewitt PL, Norton GR. The beck anxiety inventory: a psychometric analysis. Psychological Assess. 1993;4:408\u201312.","journal-title":"Psychological Assess"},{"key":"3272_CR49","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0887-6185(96)00033-3","volume":"11","author":"RI Kabacoff","year":"1997","unstructured":"Kabacoff RI, Segal DL, Hersen M, Van Hasselt VB. Psychometric properties and diagnostic utility of the Beck Anxiety Inventory and the State-Trait Anxiety Inventory with older adult psychiatric outpatients. J Anxiety Disord. 1997;11:33\u201347.","journal-title":"J Anxiety Disord"},{"key":"3272_CR50","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1002\/cncr.22980","volume":"110","author":"M Miovic","year":"2007","unstructured":"Miovic M, Block S. Psychiatric disorders in advanced cancer. Cancer. 2007;110:1665\u201376.","journal-title":"Cancer"},{"key":"3272_CR51","doi-asserted-by":"publisher","first-page":"E44","DOI":"10.1503\/cmaj.170691","volume":"190","author":"BD Thombs","year":"2018","unstructured":"Thombs BD, Kwakkenbos L, Levis AW, Benedetti A. Addressing overestimation of the prevalence of depression based on self-report screening questionnaires. Cmaj. 2018;190:E44\u2013e49.","journal-title":"Cmaj"},{"key":"3272_CR52","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1200\/JCO.2017.77.1097","volume":"36","author":"G Rodin","year":"2018","unstructured":"Rodin G, Lo C, Rydall A, Shnall J, Malfitano C, Chiu A, et al. Managing Cancer and Living Meaningfully (CALM): a randomized controlled trial of a psychological intervention for patients with advanced cancer. J Clin Oncol. 2018;36:2422\u201332.","journal-title":"J Clin Oncol"},{"key":"3272_CR53","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1515\/tnsci-2016-0007","volume":"7","author":"D \u0160vob \u0160trac","year":"2016","unstructured":"\u0160vob \u0160trac D, Pivac N, M\u00fcck-\u0160eler D. The serotonergic system and cognitive function. Transl Neurosci. 2016;7:35\u201349.","journal-title":"Transl Neurosci"},{"key":"3272_CR54","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.1038\/s41380-020-00870-9","volume":"26","author":"T Huang","year":"2021","unstructured":"Huang T, Balasubramanian R, Yao Y, Clish CB, Shadyab AH, Liu B, et al. Associations of depression status with plasma levels of candidate lipid and amino acid metabolites: a meta-analysis of individual data from three independent samples of US postmenopausal women. Mol psychiatry. 2021;26:3315\u201327.","journal-title":"Mol psychiatry"},{"key":"3272_CR55","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.psyneuen.2014.03.013","volume":"45","author":"J Quak","year":"2014","unstructured":"Quak J, Doornbos B, Roest AM, Duivis HE, Vogelzangs N, Nolen WA, et al. Does tryptophan degradation along the kynurenine pathway mediate the association between pro-inflammatory immune activity and depressive symptoms? Psychoneuroendocrinology. 2014;45:202\u201310.","journal-title":"Psychoneuroendocrinology"},{"key":"3272_CR56","doi-asserted-by":"publisher","first-page":"34","DOI":"10.2174\/138955713804484794","volume":"13","author":"G Tuboly","year":"2013","unstructured":"Tuboly G, V\u00e9csei L. Somatostatin and cognitive function in neurodegenerative disorders. Mini Rev Med Chem. 2013;13:34\u201346.","journal-title":"Mini Rev Med Chem"},{"key":"3272_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.107983","volume":"167","author":"SL Robinson","year":"2020","unstructured":"Robinson SL, Thiele TE. A role for the neuropeptide somatostatin in the neurobiology of behaviors associated with substances abuse and affective disorders. Neuropharmacology. 2020;167:107983.","journal-title":"Neuropharmacology"},{"key":"3272_CR58","doi-asserted-by":"publisher","first-page":"595","DOI":"10.3233\/JAD-2009-1165","volume":"18","author":"GS Watson","year":"2009","unstructured":"Watson GS, Baker LD, Cholerton BA, Rhoads KW, Merriam GR, Schellenberg GD, et al. Effects of insulin and octreotide on memory and growth hormone in Alzheimer\u2019s disease. J Alzheimers Dis. 2009;18:595\u2013602.","journal-title":"J Alzheimers Dis"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-025-03272-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-025-03272-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-025-03272-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T19:03:09Z","timestamp":1747854189000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-025-03272-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3272"],"URL":"https:\/\/doi.org\/10.1038\/s41398-025-03272-z","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,21]]},"assertion":[{"value":"15 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declared no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This cross-sectional study was approved by the Medical Ethical Committee of the NKI (NL6123803117) and carried out in accordance with the principles of the Declaration of Helsinki and following institutional guidelines and regulations. All patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"176"}}